Cancer News
OncoLink Cancer News - HealthDay


Frequent Dosing Can Improve Survival in Ovarian Cancer

-- A. Agrawal, PhD

Monday, September 21, 2009

MONDAY, Sept. 21 (HealthDay News) -- More frequent dosing with paclitaxel combined with carboplatin improves survival in women with advanced ovarian cancer, according to a study published early online Sept. 20 in The Lancet to coincide with the European Cancer Organisation meeting in Berlin.

As part of an open label Phase III trial, Noriyuki Katsumata, M.D., from the National Cancer Center Hospital in Tokyo, and colleagues randomly assigned 631 women with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer to conventional treatment with paclitaxel plus carboplatin (every three weeks), or dose-dense paclitaxel (once a week) plus carboplatin (every three weeks).

After a median follow-up of 29 months, the researchers found that the median progression-free survival was significantly longer in the dose-dense group (28.0 versus 17.2 months; hazard ratio, 0.71). Three-year overall survival was also significantly longer in patients receiving the dose-dense regimen (72.1 versus 65.1 percent; hazard ratio, 0.75). More patients in the dose-dense group had neutropenia and high-grade anemia and discontinued treatment early, while the frequency of other toxic effects was similar.

"The use of such dose-dense therapy should be decided on an individual basis together with other options for women with advanced-stage ovarian cancer, including intraperitoneal therapy, neoadjuvant treatment, or substitution of docetaxel," Michael A. Bookman, M.D., from the Arizona Cancer Center in Tucson comments in an accompanying editorial.

Three study authors reported financial ties to Bristol-Myers Squibb.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Specialties Cardiology
Diabetes & Endocrinology
Internal Medicine
Family Practice

Copyright © 2009 ScoutNews, LLC. All rights reserved.


I Wish You Knew

The culture of a patient is important

View More







OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More